CB-103 is a selective inhibitor of the Notch signaling pathway, primarily investigated for its potential in cancer therapy. It targets key interactions in the Notch pathway, which is involved in tumor growth, survival, and proliferation of cancer cells. This makes CB-103 a promising candidate for treating certain types of cancers, particularly those resistant to conventional therapies. Ongoing research explores its efficacy and safety in clinical settings, focusing on its ability to disrupt oncogenic signaling networks. Additionally, CB-103 is being studied for enhancing the effectiveness of other cancer treatments in combination therapies, as well as its potential applications in Notch-related conditions such as neurological disorders and inflammatory diseases.